Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Non Operating Income (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Non Operating Income for 8 consecutive years, with -$124000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 500.0% to -$124000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27000.0 through Dec 2025, down 89.2% year-over-year, with the annual reading at $27000.0 for FY2025, 89.2% down from the prior year.
  • Non Operating Income hit -$124000.0 in Q4 2025 for Protagonist Therapeutics, down from $33000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $141000.0 in Q3 2024 to a low of -$195000.0 in Q1 2023.
  • Historically, Non Operating Income has averaged -$8052.6 across 5 years, with a median of -$13000.0 in 2021.
  • Biggest five-year swings in Non Operating Income: surged 646.15% in 2022 and later crashed 1600.0% in 2023.
  • Year by year, Non Operating Income stood at -$13000.0 in 2021, then soared by 646.15% to $71000.0 in 2022, then plummeted by 38.03% to $44000.0 in 2023, then decreased by 29.55% to $31000.0 in 2024, then plummeted by 500.0% to -$124000.0 in 2025.
  • Business Quant data shows Non Operating Income for PTGX at -$124000.0 in Q4 2025, $33000.0 in Q3 2025, and $36000.0 in Q2 2025.